38
Participants
Start Date
June 21, 2011
Primary Completion Date
June 9, 2022
Study Completion Date
June 9, 2022
Ambrisentan
open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
GSK Investigational Site, Budapest
GSK Investigational Site, Ciudad de Buenos Aires
GSK Investigational Site, Córdoba
GSK Investigational Site, Guymallen
GSK Investigational Site, New York
GSK Investigational Site, Berlin
GSK Investigational Site, San Donato Milanese (MI)
GSK Investigational Site, Madrid
GSK Investigational Site, Toulouse
GSK Investigational Site, Pessac
GSK Investigational Site, Giessen
GSK Investigational Site, Paris
GSK Investigational Site, Aurora
GSK Investigational Site, Moscow
GSK Investigational Site, Novosibirsk
GSK Investigational Site, Kemerovo
GSK Investigational Site, Boston
GSK Investigational Site, Ann Arbor
GSK Investigational Site, Rome
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
Lead Sponsor
GlaxoSmithKline
INDUSTRY